Thyroid-Associated Ophthalmopathy Clinical Trial
Official title:
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
The primary objective of this study is to investigate the efficacy, safety, and tolerability
of RV 001 (teprotumumab), a fully human anti-IGF1R antibody, administered q3W for 6 months,
in comparison to placebo, in the treatment of participants suffering from active TED.
"Funding Source - FDA OOPD"
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03948191 -
99Tc-MDP for Thyroid-Associated Ophthalmopathy
|
Phase 4 | |
| Completed |
NCT02693808 -
New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression
|
N/A | |
| Completed |
NCT01599273 -
Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections
|
Phase 4 | |
| Completed |
NCT01579539 -
The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy
|
Phase 3 | |
| Recruiting |
NCT02203682 -
Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy
|
Phase 2 | |
| Terminated |
NCT00288522 -
Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment
|
Phase 2 | |
| Recruiting |
NCT04936854 -
Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease
|
Phase 2 | |
| Completed |
NCT00595335 -
Trial of Rituximab for Graves' Ophthalmopathy
|
Phase 2/Phase 3 |